Trial · NCT00424021
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 26 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the SGA (LOCF) (Week 204) | 180 weeks (Week 24 to Week 204) | Primary efficacy analyses were performed for the AMB-220-E analysis set (all subjects who received at least 1 dose of study drug during the AMB-220-E study). Results are presented using the last-observation-carried-forward (LOCF) imputation. | Units on a Scale | MEAN |
| SECONDARY | Time to Clinical Worsening of PAH | Week 0 (NCT00046319 baseline) to Week 360 | The NCT00046319 analysis set (all subjects who received at least 1 dose of study drug during the AMB-220 study) was evaluated during the NCT00046319 and AMB-220-E study periods. | Probability (%) | NUMBER |
| SECONDARY | Failure-free Treatment Status | Week 0 (NCT00046319 baseline) to Week 360 | The NCT00046319 analysis set (all subjects who received at least 1 dose of study drug during the NCT00046319 study) was evaluated during the NCT00046319 and AMB-220-E study periods. | Probability (%) | NUMBER |
| SECONDARY | Long-term Survival | Week 24 (AMB-220-E baseline) to Week 329.3 | The AMB-220-E analysis set (all subjects who received at least 1 dose of study drug during the AMB-220-E study) was evaluated during the AMB-220-E study period. | Probability (%) | NUMBER |
| PRIMARY | Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Moderate Severity During Long-term Ambrisentan Exposure | Week 24 (AMB-220-E baseline) to Week 329.3 | The AMB-220-E population consisted of all subjects who received at least 1 dose of study drug during the AMB-220-E study. | Participants | NUMBER |
| PRIMARY | Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Mild Severity During Long-term Ambrisentan Exposure | Week 24 (AMB-220-E baseline) to Week 329.3 | The AMB-220-E population consisted of all subjects who received at least 1 dose of study drug during the AMB-220-E study. | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00424021/outcomes?page=2